Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 28, 2024 16:30 ET
|
Pyxis Oncology
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,...
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
June 10, 2024 07:30 ET
|
Pyxis Oncology
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,...
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
May 30, 2024 07:30 ET
|
Pyxis Oncology
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,...
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
May 14, 2024 07:30 ET
|
Pyxis Oncology
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106...
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
May 09, 2024 07:30 ET
|
Pyxis Oncology
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,...
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024 16:30 ET
|
Pyxis Oncology
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,...
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
March 27, 2024 07:30 ET
|
Pyxis Oncology
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s...
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
March 21, 2024 07:30 ET
|
Pyxis Oncology
PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private...
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
March 13, 2024 08:00 ET
|
Pyxis Oncology
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,...
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
March 07, 2024 16:30 ET
|
Pyxis Oncology
BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,...